Iftikhar Ch

Dr. Iftikhar Ch

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2025 in International Journal of Cardiology Cardiovascular Risk and Prevention
Verified
Journal Article
Open access
HSHumza Saeed
Humza Saeed
UMUzair Majeed
Uzair Majeed
MIMinahil Iqbal
Minahil Iqbal
SSSufyan Shahid
Sufyan Shahid
AHAnum Touseef Hussain
Anum Touseef Hussain
NTNaeem Khan Tahirkheli
Naeem Khan Tahirkheli
Cancer patients are at an increased risk for the incidence and complications of acute myocardial infarction (AMI) due to shared risk factors and treatment-related adverse effects. Mortality trends for AMI-related deaths in adult cancer patients in the U.S. remain unexplored. This study used CDC WONDER data for death certificates from 1999 to 2020, identifying U.S. adults (≥25 years) with cancer (ICD-10: C00-D49) who died of AMI (ICD-10: I21) as the underlying cause. Age-adjusted mortality rates (AAMRs) and annual percent changes (APCs) were calculated and stratified by gender, age, race, and geographic location. Between 1999 and 2020, there were 109,462 AMI-related deaths in adult cancer patients. The AAMR decreased from 4.3 per 100,000 in 1999 to 1.4 in 2020. A significant decline occurred from 1999 to 2015 (APC: 6.65; 95 % CI: 6.95 to −6.40; p < 0.001), followed by a stable trend from 2015 to 2020 (APC: 1.36; 95 % CI: 2.69 to 0.91; p = 0.152). Men had higher AAMRs than women (3.5 vs. 1.5). AAMRs were highest in older adults (10.5) compared to middle-aged (0.7) and young adults (0.1). Racial disparities showed the highest AAMRs in non-Hispanic (NH) Black patients (2.7), followed by NH Whites (2.4), NH American Indian/Alaska Native (1.6), Hispanic/Latino (1.3), and NH Asian/Pacific Islander (1.1). Non-metropolitan areas had higher AAMRs than metropolitan areas (2.8 vs. 2.2). This analysis highlights a significant decline in AMI-related mortality among cancer patients in the U.S., with persistent disparities by gender, age, race and geographical location.

11 December 2024 in Annals of Thoracic Surgery Short Reports
Verified
Journal Article
Open access
ICIftikhar Ch
Iftikhar Ch
FLFaisal Latif
Faisal Latif
AUAhmad Usmani
Ahmad Usmani
JGJeffrey Garrett
Jeffrey Garrett
PWPei-Tzu Wu
Pei-Tzu Wu
NTNaeem Tahirkheli
Naeem Tahirkheli
Dual antiplatelet therapy (DAPT) has demonstrated survival benefits in patients undergoing coronary artery bypass grafting (CABG) for acute coronary syndrome. The impact of DAPT in patients undergoing elective CABG remains underexplored. This single-center retrospective observational study reviewed all CABG procedures performed between 2012 and 2015. The primary outcome measured was the difference in mortality (all-cause and cardiovascular) between patients receiving aspirin monotherapy and those on DAPT. Secondary outcomes included post-CABG acute coronary syndrome, cerebrovascular accident, and major adverse cardiovascular events. Among the 1828 patients who underwent elective CABG surgery, those who received DAPT had lower rates of all-cause mortality (odds ratio [OR], 0.43; 95% CI, 0.28-0.66; P < .001) and cardiovascular mortality (OR, 0.30; 95% CI, 0.16-0.56; P < .001) than aspirin monotherapy recipients. The overall survival rates were 93% and 97% for the aspirin monotherapy and DAPT groups, respectively (P < .001). The groups showed similar incidences of post-CABG acute coronary syndrome (OR, 1.14; 95% CI, 0.71-1.85; P = .629), post-CABG cerebrovascular accident (OR, 0.80; 95% CI, 0.45-1.43; P = .457), and major adverse cardiovascular events (OR, 0.73; 95% CI, 0.52-1.01; P = .061). Although DAPT patients experienced a higher rate of in-hospital major bleeding than aspirin monotherapy patients (OR, 1.48, 95% CI, 1.22-1.79; P < .001), the transfusion requirement was similar between the 2 groups (OR, 1.06, 95% CI, 0.77-1.46; P = .710). The use of DAPT in elective CABG patients was associated with significantly higher survival rates and reduced incidences of all-cause and cardiovascular mortality than aspirin monotherapy.

1 July 2025 in Clinical Cardiology
Verified
Journal Article
Open access
ICIftikhar Ch
Iftikhar Ch
KNKhurram Nasir
Khurram Nasir
UMUzair Majeed
Uzair Majeed
ACAzhar Chaudhry
Azhar Chaudhry
MAMuhammad Abdullah
Muhammad Abdullah
NTNaeem Tahirkheli
Naeem Tahirkheli
Background: High‐intensity statins are recommended for patients with chronic coronary artery disease, with reports suggesting improved clinical outcomes. However, recent findings in coronary artery bypass graft (CABG) patients question whether a treat‐to‐target low density lipoprotein (LDL) approach is non‐inferior to high‐intensity statin therapy.Methods: This single‐center observational study analyzed all CABG only (n = 1854) procedures performed between 2013 and 2015. Patients were divided into three groups based on statin prescription: high‐intensity statin therapy (atorvastatin ≥ 40 mg or rosuvastatin ≥ 20 mg), low/moderate‐intensity statin therapy, and a no‐statin group. The primary outcome measured was major adverse cardiovascular events (MACE), a composite of post‐CABG acute coronary syndrome, cerebrovascular accident and cardiovascular mortality.Results: No‐Statin group had significantly higher incidence of MACE compared to statin group (14.2% vs 8.9%; odds ratio (OR) 1.60, 95% confidence interval (CI) 1.055–2.427, p = 0.029). Low/moderate‐intensity therapy (n = 1301) was associated with a numerically higher overall rate of MACE compared to high‐intensity therapy (n = 397) but was not statistically significant (9.6% vs 6.6%; OR 1.45, CI 0.961–2.172, p = 0.073). Beyond 2 years post‐CABG, low/moderate intensity statin use was associated with a significant higher incidence of MACE (9.1% vs 5.3%; OR 1.72, 95% CI 0.993–2.978, p = 0.047) compared to high intensity statins.Patients who received high‐intensity statin therapy had the lowest LDL levels (82.21 ± 41.85 mg/dL), compared to those on low/moderate‐intensity statins (90.84 ± 45.89 mg/dL) and no‐statin group (104.83 ± 38.93 mg/dL, p < 0.001).Conclusion: High‐intensity statin therapy following CABG is associated with improved long‐term clinical outcomes compared to low‐ or moderate‐intensity statin regimens.

25 February 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ICIftikhar Ch
Iftikhar Ch
ACAzhar Chaudhry
Azhar Chaudhry
MZMishal Zehra
Mishal Zehra
PWPei-Tzu Wu
Pei-Tzu Wu
MTMashal Tahirkheli
Mashal Tahirkheli
NTNaeem Tahirkheli
Naeem Tahirkheli
Background: While coronary artery bypass grafting (CABG) surgery is effective in reducing the risk of myocardial infarction and subsequent cardiac events by improving myocardial perfusion, the risk of sudden cardiac death (SCD) remains notable. Methods: This retrospective observational study evaluated the efficacy of dual antiplatelet therapy (DAPT) in preventing sudden cardiac death (SCD) among patients undergoing CABG surgery at a major U.S. cardiac center (2012–2015). Data was manually extracted from electronic medical records between 23/04/2017 to 30/03/ 2018 and verified for accuracy, with patients categorized into DAPT or aspirin monotherapy groups based on discharge prescriptions. Results: Of 2,476 patients followed in this post-CABG study, the analysis included 1,005 patients who received aspirin monotherapy (AMT) and 1,458 patients who received dual antiplatelet therapy (DAPT). AMT group had a significantly higher incidence of SCD compared to those on DAPT (3.1% vs 0.8%; OR = 3.831, 95% CI: 1.961–7.519; p < 0.001). The binary regression model indicated that a higher BMI was associated with an increased risk of SCD (HR = 1.064, 95% CI: 1.012–1.118, p = 0.014). However, patients prescribed P2Y12 antagonists (HR = 0.285, 95% CI: 0.135–0.603, p < 0.001), those with a GFR > 60 ml/min (HR = 0.314, 95% CI: 0.158–0.624, p < 0.001), and those with a higher ejection fraction (HR = 0.962, 95% CI: 0.939–0.986, p = 0.002) were less likely to experience SCD following CABG. A 1 kg/m2 increase in BMI is associated with a 6.4% increase in the risk of SCD. Morbidly obese patients with BMI > 35 were more likely to have experienced SCD than those with BMI < 35 (HR = 2.400, 95% CI: 1.204–4,787; p = 0.013). Similarly, patients with EF > 40% had decreased incidence of SCD compared to those with EF < 40% (HR 0.347, 95% CI:0.158–0.763; p = 0.008). Patients on AMT had higher all-cause (OR = 2.136, 95% CI 1.502–3.038; p < 0.001) and CV mortality (OR = 3.731, 95% CI 2.233–6.235; p < 0.001) but had lower incidence of major bleeding (by drop in hemoglobin criteria) (OR = 0.704, 95% CI: 0.595–0.833; p < 0.001) compared to the DAPT group. Conclusion: DAPT prescription after CABG improves survival and lowers risk of sudden cardiac death.

16 April 2025 in Journal of Cardiothoracic Surgery
Verified
Journal Article
Open access
PDF file
ICIftikhar Ch
Iftikhar Ch
KNKhurram Nasir
Khurram Nasir
ACAzhar Chaudhry
Azhar Chaudhry
PWPei-Tzu Wu
Pei-Tzu Wu
MSMuhammad Siddique
Muhammad Siddique
NTNaeem Tahirkheli
Naeem Tahirkheli
Despite advancements in surgical techniques, interventional procedures, novel pharmacotherapies, and other contemporary treatments, patients after coronary artery bypass graft surgery (CABG) remain at risk for graft failure and progression of native vessel disease progression. Consequently, secondary revascularization is often required. This is a retrospective observational study evaluating the incidence, trends, and predictors of revascularization after CABG surgery. Of 2,476 patients followed in this post-CABG study, 1458 patients received dual antiplatelet therapy (DAPT) compared to 1005 patients received aspirin monotherapy (AMT). The overall incidence of revascularization was significantly higher in the DAPT group (14.54%, 212 out of 1458) compared to the AMT group (7.07%, 71 out of 1005), with an odds ratio (OR) of 2.24 (95% CI: 1.69–2.97, p < 0.001). 770 patients who received DAPT for six months or more after surgery were compared in sub-analysis and were noted to have significantly higher incidence of revascularization compared to AMT (22.08% vs. 6.96%; OR = 3.157, 95% CI: 2.734–4.940; p < 0.001). The binary regression model revealed that younger patients ( hazard ratio (HR) = 0.964, 95% CI: 0.95–0.97; p < 0.001), diabetics (HR = 1.50, 95% CI: 1.12-2.00, p = 0.007), patients who had fewer internal mammary artery grafts (HR = 0.54, 95% CI: 0.36–0.81, p = 0.003), and patients receiving DAPT of any duration after CABG (HR = 3.47, 95% CI: 2.55–4.72, p < 0.001) were more likely to receive revascularization after CABG. The model, comprising these four predictors, was able to explain 12.8% of the variance in post-CABG revascularization (Nagelkerke R² = 0.128; p < 0.001). The survival rates were 96.5% for the DAPT group and 92.0% for AMT (odds ratio (OR) = 0.421, 95% confidence interval (95% CI): 0.269–0.658; p < 0.001). Diabetes mellitus, younger age, fewer Internal mammary artery grafts, and the use of DAPT after CABG were strong predictors of the need for secondary revascularization.

17 December 2025 in medRxiv
Verified
Preprint
Open access
PDF file
ICIftikhar Ch
Iftikhar Ch
ACAzhar Chaudhry
Azhar Chaudhry
FJFazal Jalil
Fazal Jalil
YAYasir Ali
Yasir Ali
WIWaseem Iqbal
Waseem Iqbal
KNKhurram Nasir
Khurram Nasir
Background/Objectives: Coronary artery disease (CAD) remains the leading cause of mortality worldwide, with South Asia bearing a disproportionately high and rising burden, particularly at younger ages. This pilot study aimed to investigate genetic variants associated with premature coronary artery disease (PCAD) using whole genome sequencing (WGS). Methods: WGS was conducted on 12 people (5 PCAD cases, 7 matched controls) to assess feasibility and methodology for future large-scale research. High-quality genomic DNA was sequenced at a minimum read depth of 10× with a quality threshold of Q30. Variant calling with stringent quality control identified single nucleotide polymorphisms (SNPs), followed by annotation against gnomAD for allele frequencies and ClinVar for pathogenicity. Protein-coding variants were filtered, and candidate genes were prioritized for comparative analysis between cases and controls. Results: An average of over 8.8 million SNPs per individual was identified, with comparable overall variant distributions between cases and controls. Initial analyses revealed 120 SNPs exclusively present in PCAD cases. All protein-coding variants were rare (allele frequency <0.0001), and none were previously classified as pathogenic in ClinVar. After filtration, 87 candidate genes were prioritized. Enriched or unique variants in PCAD cases are mapped to genes involved in lipid metabolism, endothelial dysfunction, inflammatory signaling, immune regulation, thrombosis, vascular remodeling, and metabolic processes. Additional variants were identified in genes related to smooth muscle proliferation, oxidative stress, and other biological pathways. Conclusions: This WGS pilot study provides an initial overview of the genomic landscape of PCAD in a South Asian cohort, highlighting potential rare variants across multiple biological pathways implicated in atherosclerosis that needs validation in a large-scale study. Graphical